European Psychiatry - Volume 33 - March 2016

78 / 812

S74 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S72–S115
Anxiety disorders and somatoform disorders
FC05
Searching for new markers of panic
disorder – the examination of stem
cells mobilization and levels of factors
involved in their trafficking
Jolanta Kucharska-Mazur ∗, Marcin Jabło ´nski ,
Maciej Tarnowski , Barbara Doł˛egowska , Z. Ratajczak Mariusz ,
Jerzy Samochowiec
1 Department of Psychiatry, Pomeranian University of Medicine,
Szczecin, Poland
2 Department of Physiology, Pomeranian University of Medicine,
Szczecin, Poland
3 Department of Medical Analytics, Pomeranian University of
Medicine, Szczecin, Poland
4 Stem Cell Biology Program at the James Graham Brown Cancer
Center, University of Louisville, Louisville, KY 40202, USA
∗ Corresponding author.
Introduction Regeneration processes are the new target in look-
ing for biological markers of psychiatric disorders.
Aims In this study, we considered the role of stem cells and fac-
tors responsible for their trafficking in panic disorder (PD).
Methods A group of 30 patients with panic disorder was
examined and compared with a group of 30 healthy vol-
unteers. In peripheral blood we have analysed: the number
of hematopoetic stem cells – HSC (Lin−/CD45+/CD34+) and
HSC (Lin−/CD45+/AC133+), the number of very small embry-
onic – like stem cells – VSEL (Lin −/CD45−/CD34+) and VSEL
(Lin−/CD45−/CD133+) and concentration of stromal derived
factor-1 (SDF-1), sphingosine-1-phosphate (S1P), and some pro-
teins of the complement cascade.
Results Peripheral blood concentration of HSCs
(Lin−/CD45+/AC133+) was significantly lower in PD group com-
pared to control group, before and after antidepressant treatment.
Peripheral blood concentration of VSEL (Lin−/CD45 −/CD133+)
was significantly lower in PD group before treatment compared
to concentration after treatment. In PD group concentrations of
factors involved in stem cell trafficking were statistically signifi-
cant lower in PD group (before and after treatment) compared to
control group.
Conclusion Examination of regeneration system seems to be use-
ful in PD diagnostics.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
Acknowledgments This work was supported by grant
POIG.01.01.02-00-109/09.
Bipolar disorders
FC06
Multimorbidity in affective disorders:
Impact on length of stay
F. Cealicu Toma ∗, J. Moamaï
University of Ottawa, Psychiatry, Gatineau, Canada
∗ Corresponding author.
Background Multimorbidity (MM) refers to the coexistence of
two or more chronic diseases in the same individual; it encom-
passes medical comorbidity (MC) and psychiatric comorbidity (PC).
Hypothesis: MM is prevalent amongst in-patients suffering from
affective disorders (AD) and also impacted on length of stay.
Aims To determine the prevalence of MMand its impact on dura-
tion of hospitalization in AD admissions.
Method This cross-sectional study was conducted using sec-
ondary data taken from discharge records of 1056 adults admitted
for AD to a Quebec-based facility, between 2006 and 2014. Distri-
bution of AD cases: 47% depression, 53% bipolar disorders.
Results The prevalence rate of MM: 85%. PC was present in 70%
of sample whereas MC was present in 62%. The median number
of comorbid illnesses was 2.7 for each study subject. The rate of
MM was not related to age or gender. Metabolic syndrome (54%),
cardiovascular diseases and chronic pain syndrome (17%) were the
most prevalent MC in both depressed and bipolar populations. Per-
sonality disorder (65%) was highest in the depression population,
whereas substance misuse (55%) was the most prevalent PC in the
bipolar subjects. A longer length of stay was correlated with MM.
However, a logistic regression analysis indicated that duration of
hospitalization was only correlated with MC.
Conclusions The observation that MM is the norm, even in this
relatively young populationwith AD. The results confirmed thatMC
prolongs hospital stay. These findings advocate strongly for inte-
grated management of psychiatric and physical health problems in
clinical practice.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
FC07
Trends of hospitalization for bipolar I
in USA: A nationwide analysis
Z. Mansuri ∗, U. Mansuri , M. Rathod , S. Shambhu , K. Karnik
1 Drexel University, School of Public Health, Philadelphia, USA
2 Icahn School of Medicine at Mount Sinai, School of Public Health,
New York, USA
3 Drexel School of Public Health, School of Public Health, Philadelphia,
USA
4 Children’s Hospital of San Antonio - Texas, Department of
Pediatrics, San Antonio, USA
∗ Corresponding author.
Objectives Bipolar I (B-I) is an important cause of morbidity and
mortality in hospitalized patients. While B-I has been extensively
studied in the past, the contemporary data for impact of B-I on cost
of hospitalization are largely lacking.
Methods We queried the Healthcare Cost and Utilization
Project’s Nationwide Inpatient Sample (HCUP-NIS) dataset
between 1998–2011 using the ICD-9 codes. Severity of comorbid
conditions was defined by Deyo modification of Charlson comor-
bidity index. Primary outcome was in-hospital mortality and
secondary outcome was total charges for hospitalization. Using
SAS 9.2, Chi2 test, t-test and Cochran-Armitage test were used to
test significance.
Results A total of 1,80,681 were analyzed; 56.29% were female
and 43.71% were male (P < 0.0001); 70.63% were white, 17.14%
black and 12.23% of other race (P < 0.0001). Rate of hospital-
ization increased from 7469.65/million to 9375.27/million from
1998–2011. Overall mortality was 0.12% and mean cost of hos-
pitalization was 19,821.50$. The in-hospital mortality increased
from 0.13% to 0.16% (P < 0.0001) and mean cost of hospitalization
increased from 12,091.31$ to 29,292.97$. Total yearly spending on
B-I related admissions increased from $0.72 million/year to $2.16
billion/year.
Conclusions While mortality has slightly increased from 1998 to
2011, the cost has significantly increased from $0.72 million/year
to $2.16 billion/year, which leads to an estimated $1.46 billion/year
additional burden to US health care system. In the era of cost
conscious care, preventing B-I related Hospitalization could save